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Abstract
Regulatory T cell (Treg) therapy for immune modulation is a promising therapeutic strategy for the treatment and
prevention of autoimmune disease and graft-versus-host disease (GvHD) after bone marrow transplantation. However, Treg
are heterogeneous and express a variety of chemokine receptor molecules. The optimal subpopulation of Treg for
therapeutic use may vary according to the pathological target. Indeed, clinical trials of Treg for the prevention of GvHD
where the skin is a major target of the anti-host response have employed Treg derived from a variety of different sources.
We postulated that for the effective treatment of GvHD-related skin pathology, Treg must be able to migrate to skin in order
to regulate local alloimmune responses efficiently. To test the hypothesis that different populations of Treg display distinct
efficacy in vivo based on their expression of tissue-specific homing molecules, we evaluated the activity of human Treg
derived from two disparate sources in a model of human skin transplantation. Treg were derived from adult blood or cord
blood and expanded in vitro. While Treg from both sources displayed similar in vitro suppressive efficacy, they exhibited
marked differences in the expression of skin homing molecules. Importantly, only adult-derived Treg were able to prevent
alloimmune-mediated human skin destruction in vivo, by virtue of their improved migration to skin. The presence of Treg
within the skin was sufficient to prevent its alloimmune-mediated destruction. Additionally, Treg expressing the skin
homing cutaneous lymphocyte antigen (CLA) were more efficient at preventing skin destruction than their CLA-deficient
counterparts. Our findings highlight the importance of the careful selection of an effective subpopulation of Treg for clinical
use according to the pathology of interest.
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Introduction
Regulatory T cells (Treg) are a population of FOXP3-
expressing CD4+ T cells that play a central role in maintenance
of self-tolerance and immune homeostasis. Treg can be divided
into two populations: thymus-derived, naturally occurring nTreg
and adaptive aTreg, induced after antigen exposure from
conventional CD4+ T cells. Both umbilical cord blood (UCB)
and adult peripheral blood (APB) contain functional Treg,
which may be expanded in vitro without loss of suppressive
capacities [1]. Human FOXP3-expressing CD4+ T cells may be
divided into FOXP3loCD45RA+ resting Treg cells, FOXP3hiC-
D45RA2 activated Treg and FOXP3loCD45RA2 cytokine-
producing non-Treg cells [2]. UCB-derived Treg consist mainly
of naı¨ve CD45RA+ cells whereas APB-derived Treg are
a mixture of naı¨ve CD45RA+ and memory CD45RO-expressing
cells [3].
Immunomodulation with Treg is a promising therapy for
autoimmune disease and for improving allograft survival after
cell or solid organ transplantation. Treg have demonstrated
efficacy in pre-clinical models [4,5], with both UCB-derived and
APB-derived nTreg therapy progressing to phase 0/I clinical
trials for the prevention of graft-versus-host disease (GvHD)
after bone marrow transplantation (BMT) [6,7]. However nTreg
are not a homogeneous population, as different subpopulations
of Treg express distinct levels of functional molecules. Dissim-
ilarities are particularly evident in the expression of tissue-
specific homing receptors and molecules associated with
a memory phenotype [2,8,9,10,11,12]. Treg act both systemi-
cally and locally, with the local effects being critical for their
immunoregulatory capabilities [8,11,13,14,15]. For the treat-
ment of GvHD-related skin pathology, we postulated that Treg
must be able to migrate to skin in order to regulate local
alloimmune responses efficiently. To test the hypothesis that
different populations of Treg display distinct efficacy in vivo
based on their expression of tissue-specific homing molecules,
we evaluated the activity of human Treg derived from two
disparate sources in a model of human skin transplantation
[16].
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Results and Discussion
Allograft-infiltrating Human Treg Protect Human Skin
from Destruction by Allogeneic Peripheral Blood
Mononuclear Cells (PBMC)
We treated humanised BALB/c Rag22/2cc2/2 mice that were
transplanted with a human skin allograft with ex vivo-expanded
human Treg derived from healthy adult donors. Treatment with
Treg robustly extended the survival of human skin allografts in
a dose-dependent manner (Figure 1A). 40 days after the adoptive
transfer of cells, a significant number of intragraft human FOXP3+
cells together with increased intragraft FOXP3 gene expression was
detected in human skin grafts from mice treated with Treg
(Figures 1B and 1C). These intragraft FOXP3+ cells persisted
beyond 100 days within long-term surviving skin grafts
(Figure 1D). Detection of human FOXP3+ cells in skin-draining
lymph nodes by flow cytometry proved challenging due to their
relatively low frequency. To overcome this challenge, BALB/c
Rag22/2cc2/2 mice were transplanted with human skin and
reconstituted with CD4+-depleted PBMC with or without an
additional inoculation of Treg, and the skin-draining and
contralateral axillary lymph nodes analysed by flow cytometry
for the presence of human CD4+ cells. In this system, where the
only human CD4+ cells present are Treg, CD4+ cells were found
to preferentially home to the skin-draining lymph nodes
(Figure 1E). To confirm the functionality of the FOXP3+ human
cells within the skin allograft, long-term surviving human skin
allografts from Treg-treated mice or mice not receiving human
cells were retransplanted onto mice that were then reconstituted
with fresh PBMC (Figure 1F). Skin re-transplants taken from
Treg-treated mice survived long-term whereas re-transplants taken
from mice not receiving human cells were rejected with normal
kinetics (Figure 1G). In summary, therapeutic Treg home to and
infiltrate human skin allografts in sufficient numbers to control
alloresponses locally to prevent graft destruction.
Ex Vivo-expanded Human Treg Derived from APB or UCB
Display Different Skin-Homing Molecule Expression
Patterns but Similar in vitro Suppressive Potency
Therapeutic Treg that have been trialled clinically for the
prevention of GvHD have been derived and expanded in vitro from
either APB or UCB [6,7]. However, Treg are not necessarily
a homogeneous population and functional changes in Treg may
occur with aging [2,17]. We expanded human Treg from APB and
UCB and analysed their expression of FOXP3, CD127, cutaneous
lymphocyte antigen (CLA), CD62L and CCR7. CLA is a key
homing molecule for the migration of leukocytes to skin [9,18].
Expanded populations of APB-derived and UCB-derived Treg
contained similar proportions of FOXP3+CD127lo cells
(Figure 2A). In contrast, APB-derived Treg displayed a higher
CLA mean fluorescence intensity (MFI) than UCB-derived Treg
(Figure 2B). APB is known to contain a higher frequency of
CD45RO+ Treg than UCB [17]. Interestingly, it is this CD45RO+
fraction of cells that contained the highest frequency of CLA
positivity (Figure 2C). Of note, we tested the expression of other
skin homing receptors including CCR4 and CCR6 but found no
difference in the levels of expression between APB and UCB-
derived Treg (data not shown). APB-derived Treg also displayed
a higher MFI for the lymphoid homing receptors CD62L and
CCR7 (Figures 2D and 2E). Expression of FOXP3 is critical for
the regulatory activity of Treg [19]. As APB-derived and UCB-
derived Treg contain a similar frequency of FOXP3+ cells, it
would therefore follow that the suppressive efficacy in vitro would
be similar for both populations. Indeed, in a CFSE proliferation
assay, both populations of Treg suppressed the proliferation of
non-autologous CD8+ and CD4+ responders to a similar degree
(Figures 2F, 2G and 2H).
APB-derived Treg are More Effective at Suppressing
Alloresponses Against Human Skin in vivo
To determine whether APB-derived Treg are more effective
in vivo by virtue of their expression of skin-homing molecules, we
reconstituted human skin-transplanted BALB/c Rag22/2cc2/2
mice with allogeneic PBMC and treated separate groups of
mice with non-autologous Treg derived from either APB or
UCB. Only Treg derived from APB were effective at
significantly prolonging the survival of the skin transplant,
achieving a median survival time (MST) of 67 days compared
with 37.5 days using UCB-derived Treg or PBMC alone
(Figure 3A). At day 40 post-adoptive transfer of cells,
a significantly higher number of human CD4+CD25hi cells
was detected in the skin-draining axillary lymph node of mice
treated with APB-derived Treg compared with UCB-derived
Treg (Figure 3B). A similar trend was observed in the
contralateral lymph node, indicating that APB-derived Treg
have a higher propensity to migrate to lymphoid tissue and in
particular to the allograft-draining lymph node. Moreover,
a higher number of human CD4+CD25hi and FOXP3+ cells
was detected in the skin graft by flow cytometry and
immunohistochemistry in mice treated with APB-derived Treg
compared to UCB-derived Treg (Figures 3C and 3D). At day
40 after adoptive transfer, the number of allograft-infiltrating
CD4+ and CD8+ T cells was reduced in mice treated with APB-
derived Treg as compared to those treated with UCB-derived
Treg (Figure 3E). Importantly, in mice treated with APB-
derived Treg, FOXP3+ cells could be visualised throughout the
skin transplant at day 40 post-adoptive transfer (Figure 3F) and
even remained detectable beyond 100 days (Figure 3G).
CLA+ Treg Home to the Skin and are More Effective at
Preventing Skin Allograft Destruction than CLA2 Treg
As the presence of Treg within a skin graft is sufficient to
prevent its alloimmune-mediated destruction (Figure 1F and
1G), we hypothesised that Treg capable of migrating to skin are
more effective at suppressing alloresponses against skin in vivo.
Having demonstrated a higher expression of the skin homing
molecule CLA on APB-derived Treg and higher numbers of Treg
within skin grafts of mice treated with APB-derived Treg, we
investigated the hypothesis that CLA expressing APB-derived
Treg will be more efficient at preventing human skin allograft
destruction than their CLA2 counterparts. Human skin-trans-
planted BALB/c Rag22/2cc2/2 mice were reconstituted with
allogeneic PBMC and non-autologous APB-derived Treg that
were sorted based on their CLA expression, or whole unsorted
Treg (all from the same donor). CLA+ Treg were effective at
prolonging the survival of the skin transplant, achieving an MST
of .100 days compared with 71 days using CLA2 Treg (p,0.05)
or 72.5 days using whole unsorted Treg (Figure 4A). Importantly,
a higher frequency of CD4+CD25hi cells within the skin allografts
was detected in mice treated with CLA+ Treg as compared with
CLA2 Treg (Figure 4B).
In summary, we have demonstrated that the ability of Treg
to home to skin is important in determining their efficacy in
preventing alloimmune-mediated damage. Treg populations that
do not express the necessary tissue-homing molecules are
therefore less effective at preventing skin pathology in vivo
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Figure 1. Therapeutic human Treg migrate to the human skin allograft and its draining lymph node to prevent skin destruction. (A)
Therapy with ex vivo-expanded human Treg promotes the long-term survival of human skin allografts in a dose-dependent manner (**p=0.0061;
*p=0.0386, median survival time=MST). In human skin allografts from Treg-treated mice at day 40 post-adoptive transfer of cells, an increase in the
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despite exhibiting similar levels of in vitro suppressive activity.
Duhen and colleagues recently phenotyped human Treg
according to the expression of a number of chemokine
receptors, identifying four separable populations of FOXP3+
cells with similar in vitro suppressive activity [10]. One of these
populations displayed a phenotype that mirrored Th22 cells
number of human CD4+FOXP3+ (huFOXP3+) cells is present in the skin allograft, as measured by (B) immunohistochemistry and (C) qPCR for FOXP3.
(D) HuFOXP3+ cells are visualised in regulated human skin allografts over 100 days post-adoptive cellular transfer. (E) Mice received a human skin
allograft and an injection of CD4+-depleted PBMC (-CD4+ group), CD4+-depleted PBMC with human Treg (+Treg group), or unmanipulated PBMC
alone. In this system where the only human CD4+ (huCD4+) cells present are Treg, huCD4+ cells accumulate in the skin allograft draining lymph node
at day 21 post-adoptive transfer in mice receiving Treg (n = 3 mice per group, **p= 0.0062, *p= 0.0144, data represented as values and calculated
means). (F) Schematic representation of the experimental plan for (G), where mice received a human skin graft and an injection of PBMC, PBMC with
Treg, or no cells. Mice receiving PBMC alone rejected their skin allografts. Skin grafts on mice receiving PBMC with Treg (‘Treg-treated allografts’) or no
cells (‘Control allografts’) survived long-term. These skin grafts were retransplanted onto mice that were then reconstituted with PBMC. Skin re-
transplants from Treg-treated mice survived long-term (p= 0.0169).
doi:10.1371/journal.pone.0053331.g001
Figure 2. Ex vivo-expanded APB-derived and UCB-derived Treg express similar levels of FOXP3 and are equally suppressive in vitro,
but express dissimilar levels of skin-homing and lymphoid-homing molecules. (A) After ex vivo-expansion, APB and UCB-derived Treg
contain a similar proportion of FOXP3+CD127lo cells. Each data point corresponds to a distinct donor. (B) Expression of CLA is significantly higher in
APB-derived Treg (p= 0.0254). (C) The higher expression of CLA is related to a higher frequency of CD45RO+ cells in APB-derived Treg (*p=0.0116).
The expression of the lymphoid-homing receptors (D) CD62L and (E) CCR7 is higher in adult blood-derived Treg compared with UCB-derived Treg
(p=0.0191 and p=0.0133 respectively). Data are represented as mean +/2 standard deviation (SD). (F) CFSE-labelled CD8+ PBMC responders
stimulated with aCD3/aCD28 beads are suppressed to a similar degree by APB-derived and UCB-derived Treg. Figures indicate the percentage of
undivided CD8+ responder cells. In vitro suppression efficacy expressed as division index of both (G) CD4+ and (H) CD8+ responders is similar for both
APB-derived and UCB-derived Treg. Data are represented as individual data points with calculated means.
doi:10.1371/journal.pone.0053331.g002
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Figure 3. Only APB-derived Treg are effective at prolonging human skin allograft survival in vivo. (A) PBMC-reconstituted mice
transplanted with human skin allografts were treated with either APB-derived or UCB-derived non-autologous ex vivo-expanded human Treg at a 5:1
ratio of PBMC to Treg. Prolonged survival (MST 67 days cf. 37.5 days) was only achieved with APB-derived Treg (p= 0.0323). (B) Flow cytometric
analysis of lymph nodes from human skin-transplanted mice at day 40 post-adoptive transfer of cells demonstrating a higher number of CD4+CD25hi
cells in the skin-draining lymph node (dLN, p=0.0398) and a similar trend in the contralateral lymph node (cLN) in mice treated with APB but not
UCB-derived Treg. Data are represented as mean +/2 SD. (C) Similarly, in the skin graft a higher number of CD4+CD25hi cells was detected by flow
cytometry in mice treated with APB-derived compared with UCB-derived Treg (p=0.0154). (D) A significantly higher number of human FOXP3+ cells
Regulatory T Cell Therapeutics
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(‘Th22-like Treg’), expressing high levels of CLA [20,21]. We
propose that preparations of APB-derived Treg contain a signif-
icant proportion of ‘Th22-like’ CLA expressing Treg, and are
thus capable of efficiently regulating skin inflammatory re-
sponses. The migratory capabilities of Treg are important in the
prevention of autoimmune as well as alloimmune pathologies:
was detected by immunohistochemistry in skin allografts from mice treated with APB-derived Treg compared with UCB-derived Treg (examined at
day 35–40, p= 0.0273, data are represented as mean +/2 SD). (E) At day 40, a reduced number of skin infiltrating CD4+ (p,0.05) and CD8+ (not
significant) T cells was detected by immunohistochemistry in skin allografts from mice treated APB-derived Treg compared with UCB-derived Treg. (F)
At day 40, human FOXP3+ cells are visible throughout the dermis and epidermis of human skin grafts from APB-derived Treg-treated mice but not
UCB-derived Treg-treated mice. (G) At day 100, human FOXP3+ cells remain visible throughout human skin grafts from mice treated with APB-derived
but not UCB-derived Treg.
doi:10.1371/journal.pone.0053331.g003
Figure 4. Skin-homing CLA+ Treg are more effective at preventing allograft destruction than CLA2 Treg. (A) APB-derived Treg were sorted into
CLA+ and CLA2 subpopulations and adoptively transferred together with non-autologous PBMC at a 5:1 ratio of PBMC to Treg into mice previously
transplanted with a human skin allograft. A further group of mice received unsorted APB-derived Treg. While CLA2 Treg treatment resulted in an MST
of 71, treatment with CLA+ Treg significantly prolonged skin allograft survival to beyond 100 days (p= 0.0389). Mice receiving unsorted Treg achieved
a similar MST to those receiving CLA2 Treg (72 days, p= 0.1827). (B) In mice treated with CLA+ Treg, a higher frequency of CD4+CD25hi cells was
detected within the graft on day 100 compared to mice treated with CLA2 Treg (p=0.031).
doi:10.1371/journal.pone.0053331.g004
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the chemokine-mediated recruitment of Treg into the site of an
immune response is also important for the prevention of
autoimmune diabetes [11]. Treg that express skin-homing
molecules may therefore also be useful for the treatment of
autoimmune skin pathology [13]. The expression of lymphoid-
specific homing receptors is also important, as Treg act in the
allograft-draining lymph nodes to prevent the priming of
effector T cells [14,22,23]. However whether lymphoid-homing
alone is sufficient for the regulation of an immune response is
unclear. In an elegant mouse study by Tomura and colleagues,
Treg were shown to traffic between the skin and its draining
lymph nodes. Importantly, skin-emigrating Treg were more
effective at inhibiting cutaneous immune responses than lymph
node-resident Treg [24], suggesting that the ability of Treg to
circulate between peripheral and lymphoid tissues is important
for efficient regulation.
Numerous phenotypic markers allow the subdivision of Treg
into discrete subpopulations. For example, the differential
expression of CD45RA and CD45RO on Treg is important
for determining the capacity for proliferation and suppression
[2,17]. Here we demonstrate that the expression of CD45RO is
associated with CLA expression and is thus important in in vivo
settings where the homing of Treg to skin is necessary, such in
the treatment of GvHD-related skin pathology. Treg that are
currently in development for therapeutic use in BMT are being
derived from a variety of sources and isolated through a variety
of techniques [6,7]. Such diverse Treg populations, while
displaying similar in vitro suppressive capabilities [10] may
behave differently in vivo. It is therefore essential that a Treg
population being selected as a clinical cellular therapy for
a specific pathology expresses the necessary migratory char-
acteristics to allow its migration into the tissue where regulation
is required.
Methods
Ethics Statement
Experiments were performed using protocols approved by the
Committee on Animal Care and Ethical Review at the University
of Oxford and in accordance with the UK Animals (Scientific
Procedures) Act 1986. For the collection of human tissue samples,
this was performed with full informed written consent and with
ethical approval from the Oxfordshire Research Ethics Committee
(REC B), study number 07/H0605/130.
Mice
BALB/c Rag22/2cc2/2 (H2d) mice were housed under
specific pathogen-free conditions in the Biomedical Services Unit
of the John Radcliffe Hospital (Oxford, UK).
Animal Procedures
Skin transplantation was performed as previously described
[16]. Only mice displaying .1% splenic human leukocyte
chimerism were included in analyses.
Isolation of Skin Infiltrating Leukocytes from Human Skin
The method of isolating skin infiltrating leukocytes was adapted
from McLachlan et al. [25]. Briefly, skin was placed in ice-cold
2% FCS RPMI-1640, divided into small pieces and incubated
with 1.6 mg/ml Collagenase D (Roche) at 37uC and 5% CO2 for
30 minutes. Skin fragments were then mashed with the back end
of a syringe plunger and incubated for an additional 20–30
minutes. Skin pieces were then filtered though a 70 mn nylon
mesh, mashed again and rinsed with a solution of PBS with 5 mM
EDTA and 2% FCS. Collected cells were stained for flow
cytometric analysis.
Isolation and Expansion of Human CD127lo Regulatory T
cells
Fresh adult buffy coats and cord blood units were obtained
from the National Blood Service (UK). Isolation and expansion
of Treg was performed as previously described with minor
modifications [16]. Adult CD127loCD25+CD4+ cells were sorted
from CD25+-enriched cells using a BD FACSAria cell sorter.
Cord blood Treg isolation was performed using a CD25+
isolation kit (Miltenyi, UK). Adult Treg were expanded with
1000 U/ml of recombinant human (rh) IL-2 (Chiron) and
aCD3/aCD28 beads (Invitrogen) in a 1:3 (1st round) and 1:1
(2nd round) cell to bead ratio over two 7-day rounds, followed
by 2 days of silencing in a reduced amount of rhIL-2 (200U/
ml) and aCD3/aCD28 bead removal. Cord blood Treg were
expanded with 1000U/ml of rhIL-2 and aCD3/aCD28 beads
in a 1:3 cell to bead ratio over 14 days, followed by 2 days of
silencing.
In vitro Suppression Tests
Treg in vitro suppressive activity was assessed by measuring
inhibition of proliferation of non-autologous PBMC stimulated
with aCD3/aCD28 beads. CFSE-labelled PBMCs (56104) were
incubated for 72 hours with aCD3/aCD28 beads (16104) in the
presence of in vitro expanded Treg before analyses by flow
cytometry. A division index was calculated in a similar manner
to Roederer et al. [26].
Flow Cytometry
Fluorochrome-coupled antibodies specific for CD4 (Beckman
Coulter), CD45, CD8, CD19, CD25, CD27, CCR7, CLA,
CD127 (all BD), FOXP3, CD3, 7-AAD (eBioscience) and
CD62L (Invitrogen) were used to phenotypically profile cells.
Data were acquired using a FACSCanto and analysed using
FACSDiva software (BD).
Tissue Typing
Donor blood was analysed at the Oxford Transplant Centre
Histocompatibility Laboratory for HLA-A, -B, -Cw, -DR and –
DQ haplotypes.
Immunohistochemistry
Immunohistochemistry was performed as previously described
[16]. Snap-frozen specimens were sectioned at 8mm and stained
using mouse anti-human FOXP3 antibody (236/A, a gift from
Professor Alison Banham) and haematoxylin counterstaining. For
infiltrating cell quantification, positive cells were counted at 406
magnification in three random fields of each of four separate
sections per sample.
Statistical Analyses
Student’s t tests were applied on grouped data. Survival data
were analysed using logrank tests.
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